Acrivon Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	41.9	39.82	36.02	29.52	99.6
Short-Term Investments	95.53	139.66	91.44	98.23	-
Cash & Short-Term Investments	137.42	179.48	127.46	127.75	99.6
Cash Growth	-23.88%	40.81%	-0.23%	28.26%	-
Other Current Assets	1.19	2.35	2.65	4.73	1.19
Total Current Assets	138.41	181.63	129.69	132.1	100.41
Net Property, Plant & Equipment	8.12	8.03	7.91	6.86	5.79
Long-Term Investments	10.2	5.09	-	41.88	-
Other Long-Term Assets	1.65	1.65	0.25	-	-
Total Assets	158.58	196.59	138.27	181.23	106.59
Accounts Payable	1.16	0.76	5.05	0.9	0.96
Accrued Expenses	11.12	15.4	7.38	4.89	1.29
Current Portion of Leases	1.15	1.06	0.88	0.73	0.66
Total Current Liabilities	13.43	17.21	13.3	6.52	2.91
Long-Term Leases	2.12	2.59	3.77	4.24	4.96
Total Long-Term Liabilities	2.12	2.59	3.77	4.24	4.96
Total Liabilities	15.55	19.8	17.07	10.75	7.88
Preferred Stock	-	-	-	-	122.52
Common Stock	0.03	0.03	0.02	0.02	0
Additional Paid-in Capital	380.56	373.28	237.68	226.58	1.05
Accumulated Other Comprehensive Income	0.11	0.45	-0.08	-0.1	-
Retained Earnings	-237.66	-196.98	-116.42	-56.03	-24.87
Shareholders' Equity	143.04	176.79	121.2	170.48	-23.81
Total Liabilities & Equity	158.58	196.59	138.27	181.23	-15.93
Total Debt	3.26	3.65	4.64	4.96	5.63
Net Cash (Debt)	134.16	175.84	122.81	122.79	93.98
Net Cash Growth	-23.70%	43.17%	0.02%	30.66%	-
Net Cash Per Share	3.50	5.20	5.56	29.79	53.90
Book Value	143.04	176.79	121.2	170.48	-23.81
Book Value Per Share	3.73	5.23	5.49	41.36	-13.66
Tangible Book Value	143.04	176.79	121.2	170.48	-23.81
Tangible Book Value Per Share	3.73	5.23	5.49	41.36	-13.66

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q